MicroRNA在胃癌耐药中的作用  

MicroRNA Mediated Drug-resistance in Gastric Cancer

作　　者：边原[1] 杨勇[1] 何霞[1] 陈鸣[1] 肖洪涛[1] 李刚[1] 龙恩武[1] 

机构地区：[1]四川省医学科学院 四川省人民医院药学部,成都610072

出　　处：《药物流行病学杂志》2014年第9期568-572,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：胃癌患者治疗过程中发生的多药耐药(multidrug resistance,MDR)是导致药物治疗失败的最主要原因。既往研究热点在于挖掘耐药细胞与亲本细胞之间差异表达的基因,进而探索其介导耐药的下游分子通路,而往往忽略了导致这些基因差异表达的上游调控网络。近年来发现microRNA(miRNA)是一类广泛存在于动植物体内的非编码小RNA,在转录后水平调控基因的表达。越来越多的研究表明,miRNA广泛参与肿瘤的发生发展,并与肿瘤耐药密切相关。本文通过分析近几年miRNA与胃癌耐药的最新研究报道,以期为胃癌耐药上游调控网络的研究提供借鉴。Multidrug resistance （MDR） occurred during the treatment process of gastric cancer patients was the most important reason why the drug treatment failure. Most reports focused on the difference of expression of genes between the resistant cells and parental cells, and explored their downstream molecular pathways which mediated the occurrence of resistance. However, the upstream regulatory networks of these genes were ignored which leaded to. MicroRNAs （miR- NAs） were commonly existed in plants and animals, which was identified as a class of small non-coding RNA in post-transcriptional level. The relationship between miRNA and carcinogenesis or drug resistance had been reported in many studies. This review analyzed the latest report about miRNA mediated drug-resistant in gastric cancer, which had possibility to provide several supports for gastric resistance on terms of upstream regulatory network.

关 键 词：胃癌 耐药 MICRORNA 

分 类 号：R735.2[医药卫生—肿瘤]